Research
Research

Jazz’s development pipeline includes the clinical development of new therapies to treat unmet medical needs, line extensions for existing products, and the generation of additional clinical data for existing products.

R&D Pipeline

Pipeline

Updated 11/07/2017

1 Approved in the U.S. in August 2017 for the treatment of adults with newly-diagnosed t-AML or AML-MRC.
2 NDA submission assumes positive study outcome.
3 Expect to be ready to submit in mid-2018.
4 In 3Q17, the company entered into a collaboration and option agreement with ImmunoGen, Inc. under which the company will support ImmunoGen’s development of these investigational product candidates
5 IND submitted 3Q17; ImmunoGen expects to initiate a Phase 1 study by end of 2017.
6 Evaluation of deuterated oxybate continues as part of the once-nightly development process.
7 Evaluating early-stage product candidates, including recombinant pegaspargase.
t-AML = Therapy-Related Acute Myeloid Leukemia, AML-MRC = AML with Myelodysplasia-Related Changes, MAA = Marketing Authorization Application, ES = Excessive Sleepiness, OSA = Obstructive Sleep Apnea, NDA = New Drug Application, sNDA = Supplemental New Drug Application, VOD = Hepatic Veno-occlusive Disease, FPI = First Patient In, EDS = Excessive Daytime Sleepiness, GvHD = Graft versus Host Disease, ADC = Antibody-Drug Conjugate, ALL = Acute Lymphoblastic Leukemia